Historical valuation data is not available at this time.
Chengdu Huasun Technology Group Inc., Ltd. is a Chinese company primarily engaged in the research, development, production, and sales of biotech products, including blood plasma-based pharmaceuticals and diagnostic reagents. The company operates within the competitive biomedical sector in China, leveraging its expertise in plasma fractionation and biopharmaceutical manufacturing. Its core products include albumin, immunoglobulins, and coagulation factors, which are critical in treating various medical conditions. Huasun has established a presence in domestic markets, though it operates in a highly regulated industry with significant barriers to entry, relying on its production capabilities and compliance with national health standards.
Engages in R&D for new plasma-derived therapies and diagnostic technologies; holds patents related to plasma processing and purification methods
Chengdu Huasun Technology operates in a stable but competitive and regulated sector, with a focus on plasma-based biopharmaceuticals. Its revenue is driven by essential medical products, though detailed financial metrics are not widely available in English. Key risks include regulatory hurdles and competitive pressures. The company's growth depends on expanding its plasma supply and product pipeline, aligned with broader healthcare trends in China. Investors should monitor regulatory developments and financial disclosures closely.